NCI Committed to Increasing Minority Participation in Clinical Trials
BETHESDA, Md--Acting NCI Director Edward Sondik announced that the institute is committed to increasing participation of minorities in clinical trials. However, cancer researchers have had only limited success in this effort, he said.
BETHESDA, Md--Acting NCI Director Edward Sondik announced thatthe institute is committed to increasing participation of minoritiesin clinical trials. However, cancer researchers have had onlylimited success in this effort, he said.
Dr. Sondik's remarks were made at a meeting of a new coalition,the Intercultural Cancer Council, sponsored by Baylor Collegeof Medicine, the Susan G. Komen Breast Cancer Foundation, M.D.Anderson Cancer Center, Howard University Hospital, the AmericanCancer Society, and Kellogg Company.
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
